AHCC (Active Hexose Correlated Compound) trials recruiting now
2 registrations that name AHCC as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT06693323
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Phase 2
University of California, Irvine
About 34 people
Started Dec 4, 2024
In plain words A Phase 2 study of AHCC in people 18 to 79, run by University of California, Irvine. It plans to enroll about 34 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 79. Conditions: HNSCC; Head and Neck Squamous Cell Carcinoma.
Between 18 and 79 years of age.
Has a diagnosis of pathologically or cytologically proven HPV positive HNSCC.
For patients who have undergone surgery, they must be registered at least 4 weeks after surgery.
For patients that have completed surgery, has a high risk disease defined as:
14 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
AHCC®capsules
Registered summary
This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07118735
AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy
No phase
National Cheng-Kung University Hospital
About 94 people
Starts Aug 20, 2025 (estimated)
In plain words A study of AHCC in people 20 and older, run by National Cheng-Kung University Hospital. It plans to enroll about 94 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Liver Cancer; Hepatocellular Carcinoma.
1.Liver cancer patient who will receive immunotherapy
2.At least one measurable tumor, according to RECIST version 1.1, that has not been treated with any local procedure.
3.Age >=20 years old.
4.ECOG performance status 0 or 1.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
A standardized extract of cultured Lentinula edodes mycelia (AHCC®); Placebo
Registered summary
This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.